Octilia Allergia E Infiammazione (Pheniramine Maleate, Tetryzoline Hydrochloride)

Octilia Allergia E Infiammazione contains pheniramine maleate, an antihistamine that acts on histamine‑driven allergic pathways.

• Allergic rhinitis: reduces nasal congestion, itching and sneezing.
• Acute urticaria: alleviates hives and itching.
• Seasonal allergy symptoms: provides relief from eye and throat irritation associated with pollen exposure.

• Pheniramine maleate blocks H1 histamine receptors in peripheral tissues, preventing histamine from binding and triggering the cascade that leads to vasodilation, increased vascular permeability, and sensory nerve activation. This antagonism reduces the typical signs of allergic inflammation such as itching, swelling, and redness.

Pheniramine maleate may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Drowsiness: mild to moderate sedation.
• Dry mouth: reduced salivary flow.
• Dizziness: transient light‑headedness.
• Nausea: occasional stomach upset.
• Blurred vision: temporary visual changes.
• Constipation: slowed gastrointestinal motility.

Serious or Rare Side Effects

• Cardiac arrhythmia: irregular heartbeat.
• Severe hypotension: marked drop in blood pressure.
• Anaphylaxis: rare systemic allergic reaction.
• Hepatic dysfunction: elevated liver enzymes.
• Neuroleptic malignant‑like syndrome: rare extrapyramidal signs.
• Blood dyscrasias: unexplained bruising or bleeding.

When using pheniramine maleate, consider the following safety measures:

• Pregnancy: avoid use unless clearly needed and prescribed.
• Breastfeeding: assess risk‑benefit before use.
• Elderly patients: start with lower dose and monitor sedation.
• Concomitant CNS depressants: avoid additive drowsiness.
• Driving or operating machinery: caution due to possible sedation.
• Store at below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Pheniramine maleate can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
• Other antihistamines: heightened sedation and anticholinergic load.
• CNS depressants (benzodiazepines, opioids): amplified central nervous system depression.

Moderate Interactions (Monitor Closely)

• Alcohol: increased drowsiness.
• Anticholinergic drugs (e.g., atropine): additive dry‑mouth effects.
• CYP450 inhibitors (e.g., erythromycin): possible increased pheniramine levels.